Results 181 to 190 of about 255,779 (244)

Integrating Spatial Proteogenomics in Cancer Research

open access: yesAdvanced Science, EarlyView.
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang   +13 more
wiley   +1 more source

Mammographic radiomics and breast density for predicting PD-L1 expression in breast cancer. [PDF]

open access: yesCancer Imaging
Zhao YS   +7 more
europepmc   +1 more source

Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A zinc/manganese (Zn/Mn)‐based metal‐organic framework (MOF) loaded with the STING agonist c‐di‐AMP diammonium (denoted AMP@Zn/Mn‐MOF) was developed to synergistically activate the cGAS‐STING pathway and induce immunogenic cell death. This nanoplatform reprograms the immunosuppressive tumor microenvironment, significantly enhancing anti‐PD‐L1 ...
Bingzi Zhu   +15 more
wiley   +1 more source

Pancancer Fine‐Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
This study identifies mutation‐intolerant genes (MIGs), which are mutationally constrained in tumors despite normal‐tissue variability. Using miDriver, the authors pinpoint MIGs essential for tumor‐intrinsic fitness and immune evasion. Focusing on CHEK1, they show it drives tumor fitness and sculpts an immunosuppressive niche via the MIF–CD74 axis ...
Tao Wang   +16 more
wiley   +1 more source

Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. [PDF]

open access: yesCell Death Dis
Zhao C   +14 more
europepmc   +1 more source

Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

open access: yesAdvanced Science, EarlyView.
The inhibitory immune checkpoints HLA‐G and CD47 are expressed on certain tumor types and inhibit immune cells in the tumor microenvironment. DSP216 binds specifically to cancer cells expressing both HLA‐G and CD47, and blocks their inhibitory signaling.
Lisa J. Jacob   +12 more
wiley   +1 more source

Assessment of soluble PD-L1 in septic shock in relation to immunosuppressive phenotypes. [PDF]

open access: yesAnn Intensive Care
Bonnet C   +7 more
europepmc   +1 more source

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu   +6 more
wiley   +1 more source

Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential. [PDF]

open access: yesNeurosurg Rev
Torky RF   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy